Quote this publication Share Print

INSTANYL

-
Opinions on drugs - Posted on May 21 2013

Reason for request

Inclusion on the list of medicines reimbursed by National Insurance and approved for hospital use.

-


Clinical Benefit

Substantial

The actual benefit of these proprietary products is substantial.


Clinical Added Value

no clinical added value

The comparative data for nasal fentanyl versus oral transmucosal fentanyl did not demonstrate superiority of INSTANYL relative to the comparator sharing the same indication ; INSTANYL does not bring an improvement in actual benefit (IAB V) in comparison with therapid-acting opioids indicated in the management of breakthrough pain episodes in adult patients using opioids to treat chronic cancer-related pain.


Contact Us

Évaluation des médicaments

See also